Back to Journals » Clinical Ophthalmology » Volume 12

Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions

Authors Brewington BY, Shao YF, Davidorf FH, Cebulla CM

Received 9 August 2017

Accepted for publication 20 February 2018

Published 17 May 2018 Volume 2018:12 Pages 925—934

DOI https://doi.org/10.2147/OPTH.S129645

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser


Beatrice Y Brewington,1 Yusra F Shao,2 Fredrick H Davidorf,1 Colleen M Cebulla1

1Havener Eye Institute, Department of Ophthalmology and Visual Science, Ohio State University, 2Medical Student Research Program, The Ohio State University College of Medicine, Columbus, OH, USA

Abstract: Surgical management with enucleation was the primary treatment for uveal melanoma (UM) for over 100 years. The Collaborative Ocular Melanoma Study confirmed in 2001 that globe-preserving episcleral brachytherapy for UM was safe and effective, demonstrating no survival difference with enucleation. Today, brachytherapy is the most common form of radiotherapy for UM. We review the history of brachytherapy in the treatment of UM and the evolution of the procedure to incorporate fine-needle-aspiration biopsy techniques with DNA- and RNA-based genetic prognostic testing.

Keywords: brachytherapy, uveal melanoma, UM, fine-needle-aspiration biopsy, genetic prognostic testing, molecular markers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]